The AFU has set itself the task of setting up a register of medical practices in order to define possible improvements in the therapeutic management and follow-up of NMIBC. In order to obtain representative data, all urologists who are members of the AFU may be invited to include their patients.
Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary test (biomarker) prior to their resection (biopsy) diagnosis or recurrence,
AND adult (equal to or > 18 years old),
AND affiliated with a social security scheme in France,
AND whose monitoring will be carried out at the recruiting center.
Patient being monitored for a non-urothelial bladder tumor
Patient refusing follow-up
Opposition to participation in the study
Adult protected by law
Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary test (biomarker) prior to their resection (biopsy) diagnosis or recurrence
Case-only
Retrospective
Not listed
Recurrence-Free Survival
New bladder cancer (Whether NMIBC or MIBC).
Performance of urine tests (biomarkers)
To evaluate the diagnostic performance of urine tests (biomarkers) available in France, and providing a binary result (positive: probable presence of a tumor recurrence; negative: probable absence of a tumor recurrence) correlated to the result of the bladder endoscopy performed as part of the routine care for the follow-up of NMIBC: determination of the negative and positive predictive values of biomarkers.
Progression-Free Survival
New bladder cancer (MIBC).
Click on the lead sponsor to view all of their trials.
